The Quality in Care (QiC) partnership is proud to announce that its 2014 Anticoagulation Programme is now open for entry to teams and individuals working within the field of anticoagulation – a field of treatment involving the prevention and treatment of blood clots.
Launched today at the Clinical Pharmacy Congress 2014 in London, QiC Anticoagulation recognises, rewards and shares good practice in anticoagulation management, education and patient care.
The programme comprises both an awards event and subsequent dissemination opportunities, and has the support and active participation of key stakeholders, including Bayer and charities ACE (AntiCoagulation Europe) and The Stroke Association.
Partnership working and collaboration are key to the QiC Programme and entries are invited from the NHS, industry, private sector and patient organisations to be reviewed by a panel of judges made up of nurses, commissioners, clinicians and patient representatives.
Eve Knight, co-founder and Chief Executive, AntiCoagulation Europe said: “ACE is proud to support the Quality in Care (QiC) Anticoagulation Programme because it shares our goals of recognising best practice and enabling patients to take a more active role in their own healthcare as well as improving their quality of life.”
Marion McPherson, General Medicine Business Unit Head, Bayer HealthCare commented: “Bayer is delighted to partner the Quality in Care 2014 Anticoagulation programme. Our products and services are designed to benefit people and improve their quality of life which is why we are proud to be associated with a programme that supports the implementation of innovation and good practice in the NHS, resulting in tangible benefits for patients.”
Winners of the 2014 awards will be announced at an event recognising good practice on Tuesday September 30, 2014, at BMA House, Tavistock Square, London.
Entry details can be found at http://www.qualityincare.org/anticoagulation
The QiC Anticoagulation Partners
The QiC Anticoagulation Programme is supported by the following organisations:
Bayer HealthCare, AntiCoagulation Europe (ACE), The Stroke Association
Notes to the editor
About QiC Anticoagulation
Who can enter?
The programme is open to anyone working in the field of anticoagulation in the UK; for a patient group; in the voluntary sector; industry; in a consultancy; or people with atrial fibrillation, artificial heart valve, deep vein thrombosis (DVT), pulmonary embolism (PE), blood clots, strokes and heart attacks.
Where to enter
More information and entry forms can be found at the website www.qualityincare.org
Entry deadline: June 27, 2014
FIVE categories for 2014
· Best Primary Care Team of the Year
· Best Hospital Team of the Year
· Best Cross-Organisational Partnership
· Anticoagulation Innovation of the Year
· Lifetime Achievement Award
About the Quality in Care Programmes
QiC Programmes launched in 2011 bringing the NHS, industry and patient groups closer together to increase joint working, with the goal of recognising good practice in the UK and providing opportunities for sharing projects and initiatives that will ultimately benefit patients. This series of programmes aim to recognise, reward and share good practice in patient care within specific treatment areas. Current programmes include diabetes, oncology, anticoagulation and hepatitis C
PMGroup is a leading international multi-channel media group. Founded in 1988 it produces a range of magazines, websites and communications programmes to support the pharmaceutical industry and related sectors.
PMGroup’s online hub is its pharmaceutical industry portal http://www.pmlive.com. PMLiVE was launched in 1999 and is a trusted source of pharmaceutical news, intelligence and commentary for the pharmaceutical and biotech industries.
Each year PMGroup runs two award schemes. The Communiqué Awards commends excellence in healthcare communications and the Pharmaceutical Market Excellence Awards (PMEA) recognises pharmaceutical companies that deliver business excellence.